Compare Meta Platforms Inc (META) vs Moderna, Inc. (MRNA) Price & Performance

Meta Platforms (META) trades at $643.81, down 0.34% on the day, with strong technical momentum showing bullish moving averages and neutral oscillators. The company demonstrates robust fundamentals with 2025 revenue of $201B, net income of $60.5B, and impressive profitability margins including 81.9% gross margin and 32.8% net margin. Recent catalysts include the launch of Muse Spark AI model and consistent earnings beats, with Q1 2026 EPS of $10.44 significantly exceeding expectations of $6.70.

The outlook remains positive with analyst consensus price target of $817.32 representing 27% upside potential. Key opportunities include AI monetization through Muse Spark and strong advertising revenue growth, while risks involve ongoing litigation regarding youth addiction claims and elevated capital expenditures for AI infrastructure. Wall Street maintains strong bullish sentiment with 79% buy ratings.

Moderna (MRNA) trades at $59.66, down 3.49% in the last session amid broader biotech volatility. The stock shows a mixed technical picture with bullish overall signals but bearish moving averages. Fundamentally, revenue has declined from pandemic peaks to $1.92B in 2025, with net losses widening to -$2.82B. Recent positive developments include an EU RSV vaccine contract and progress in cancer immunotherapy trials, with Q2 2026 earnings due July 31.

Outlook remains speculative as Moderna transitions beyond COVID-19 vaccines. Opportunities lie in its expanding pipeline in oncology and flu vaccines, but risks include sustained losses, competitive pressure, and execution hurdles. Analyst consensus is cautious with a $49 price target below current levels, reflecting uncertainty over profitability timeline.